To date, there have been few reports about the effect of COVID‐19 on patients with ITP, who are at high risk of bleeding and thrombocytosis, especially those who have previously used thrombopoietin receptor agonists (TPO‐RA) [5, 6, 7]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.